{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:02:51Z","timestamp":1794009771174,"version":"4.8.0"},"reference-count":204,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by an exceptionally high global prevalence that is projected to continue rising in the near future. MASLD is strongly associated with a spectrum of cardiometabolic risk factors, and may itself, in turn, contribute to cardiovascular morbidity and mortality. This interconnection warrants the development of integrated treatment strategies targeting shared pathophysiological processes and addressing both hepatic, metabolic, and cardiovascular outcomes. In this work, we review the modern MASLD clinical development pipeline and highlight the most prominent drug candidates with known or purported cardiovascular benefits, discussing mechanistic links and supporting evidence ranging from preclinical experiments to real-world data. Although the drug development pipeline is extensive and diverse, evidence supporting cardiovascular benefits for most candidate molecules remains limited. Both of the FDA-approved therapies, resmetirom and semaglutide, have been found to significantly reduce the risk of major adverse cardiovascular events as well as cardiovascular and all-cause mortality in patients with MASH. In addition, significant improvements were observed in patients with heart failure with preserved ejection fraction treated with semaglutide, highlighting incretin mimetics as a promising class for managing cardiovascular disease concomitant with MASLD\/MASH. Other investigational compounds, targeting the farnesoid X receptor, peroxisome proliferator-activated receptors, de novo lipogenesis enzymes, and fibroblast growth factors, have demonstrated improvements in blood lipid spectrum and glycemic control; however, their clinical effectiveness in patients at cardiovascular risk has yet to be established.<\/jats:p>","DOI":"10.3390\/biomedicines14040909","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:35:42Z","timestamp":1776339342000},"page":"909","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4690-1811","authenticated-orcid":false,"given":"Veronika A.","family":"Prikhodko","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Saint Petersburg State Chemical and Pharmaceutical University, 14A Prof. Popov Str., 197022 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4294-5531","authenticated-orcid":false,"given":"Sergey V.","family":"Okovityi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Saint Petersburg State Chemical and Pharmaceutical University, 14A Prof. Popov Str., 197022 St. Petersburg, Russia"},{"name":"Scientific, Clinical and Educational Center of Gastroenterology and Hepatology, Saint Petersburg State University, 7\/9 Universitetskaya Emb., 199034 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global Burden of NAFLD and Chronic Liver Disease among Adolescents and Young Adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_4","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.iliver.2025.100195","article-title":"Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease and Donor Liver Damage","volume":"4","author":"Gou","year":"2025","journal-title":"ILIVER"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, Morbidity and Mortality of Nonalcoholic Fatty Liver Disease","volume":"111","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"111891","DOI":"10.1016\/j.diabres.2024.111891","article-title":"Role of MASLD in CVD: A Review of Emerging Treatment Options","volume":"217","author":"Mollace","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhou, X.-D., Lazarus, J.V., Krittanawong, C., Targher, G., Byrne, C.D., Younossi, Z.M., Tacke, F., Chen, Q.-F., Mantzoros, C.S., and Tilg, H. (Lancet Gastroenterol. Hepatol., 2026). Pharmacotherapy for Metabolic Dysfunction-Associated Steatohepatitis: Heart\u2013Liver Co-Management, Lancet Gastroenterol. Hepatol., Online ahead of print.","DOI":"10.1016\/S2468-1253(25)00323-1"},{"key":"ref_12","unstructured":"(2026, February 27). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"ref_13","first-page":"60","article-title":"Resmetirom: An Orally Administered, Small-Molecule, Liver-Directed, \u03b2-Selective THR Agonist for the Treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"Eur. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1021\/acs.jmedchem.5c03114","article-title":"Targeting THR-\u03b2 for MASLD Treatment: Current Progression and Emerging Prospects","volume":"69","author":"Li","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid Hormone Receptor-\u03b2 Analogues for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)","volume":"82","author":"Ratziu","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"A4140504","DOI":"10.1161\/circ.150.suppl_1.4140504","article-title":"Abstract 4140504: Effect of Resmetirom on Lipid Panel: Meta-Analysis of Randomized Controlled Trials","volume":"150","author":"Kommu","year":"2024","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106440","DOI":"10.1016\/j.ejim.2025.106440","article-title":"Effect of Resmetirom on Lipid Profile and Adiponectin Levels","volume":"141","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70056","DOI":"10.1111\/liv.70056","article-title":"A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis","volume":"45","author":"Pennisi","year":"2025","journal-title":"Liver Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S628","DOI":"10.14309\/01.ajg.0001139152.60803.d4","article-title":"S2923 Resmetirom Significantly Reduces Mortality and Complications in MASLD: A Matched Cohort Study","volume":"120","author":"Albuni","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s43162-025-00468-z","article-title":"Resmetirom in the Management of Metabolic Associated Steatohepatitis (MASH): A Review of Efficacy and Safety Data from Clinical Trials","volume":"37","author":"Ogieuhi","year":"2025","journal-title":"Egypt. J. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"goaf097","DOI":"10.1093\/gastro\/goaf097","article-title":"An Analysis of Safety Data from the First Year of Resmetirom","volume":"13","author":"Kudaravalli","year":"2025","journal-title":"Gastroenterol. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41591-025-03722-7","article-title":"TERN-501 Monotherapy and Combination Therapy with TERN-101 in Metabolic Dysfunction-Associated Steatohepatitis: The Randomized Phase 2a DUET Trial","volume":"31","author":"Noureddin","year":"2025","journal-title":"Nat. Med."},{"key":"ref_23","first-page":"13","article-title":"Results from the 52 week phase 2b VOYAGE trial of VK2809 in patients with biopsy-confirmed non-alcoholic steato-hepatitis and fibrosis: A randomized, placebo-controlled trial","volume":"20","author":"Lian","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_24","unstructured":"(2026, February 27). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_25","unstructured":"Ascletis Pharma Inc. (2026, February 27). Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis. Available online: https:\/\/www.prnewswire.com\/news-releases\/gannex-announces-positive-interim-results-from-52-week-phase-ii-clinical-trial-of-once-daily-asc41-tablet-in-patients-with-biopsy-confirmed-non-alcoholic-steatohepatitis-302024444.html."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lu, X., Wang, S., Du, Y., Xie, B., Chen, Q., Lin, J., Chen, B., and Cui, K. (2025). KYLO-0603, a Novel Liver-Targeting, Thyroid Hormone Receptor-\u03b2 Agonist for the Inhibition of MASH Progression. PLoS ONE, 20.","DOI":"10.1101\/2025.02.09.637336"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2183-LB","DOI":"10.2337\/db25-2183-LB","article-title":"2183-LB: Metabolic Effects of ECC4703, a Liver Targeting Full THRb Agonist, in Combination with Semaglutide and Tirzepatide in Diet-Induced Obese Mice","volume":"74","author":"Zhou","year":"2025","journal-title":"Diabetes"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2213-8587(25)00166-4","article-title":"Incretins and the Cardiovascular System: Bridging Digestion with Metabolism","volume":"13","author":"Avogaro","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"104213","DOI":"10.1016\/j.numecd.2025.104213","article-title":"Next Generation Dual GLP-1\/GIP, GLP-1\/Glucagon, and Triple GLP-1\/GIP\/Glucagon Agonists: A Literature Review","volume":"35","author":"Wen","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10741-024-10438-2","article-title":"Beyond Weight Loss: The Potential of Glucagon-like Peptide-1 Receptor Agonists for Treating Heart Failure with Preserved Ejection Fraction","volume":"30","author":"Wang","year":"2024","journal-title":"Heart Fail. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like Receptor Agonists and next-Generation Incretin-Based Medications: Metabolic, Cardiovascular, and Renal Benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"ref_32","first-page":"e71366","article-title":"Efficacy and Safety of GLP-1 Receptor Agonists in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"16","author":"Njei","year":"2024","journal-title":"Cureus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e0871","DOI":"10.1097\/HC9.0000000000000871","article-title":"Effect of Glucagon-like Peptide-1 Receptor Agonists on Histologic MASH: A Meta-Analysis of Randomized Controlled Trials","volume":"10","author":"Siranart","year":"2026","journal-title":"Hepatol. Commun."},{"key":"ref_34","first-page":"101708","article-title":"Efficacy and Safety of GLP-1 Receptor Agonists in MASH with Fibrosis: A Systematic Review and Meta-Analysis","volume":"8","author":"Abreu","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17474124.2023.2172397","article-title":"Comparative Efficacy of Glucagon-like Peptide 1 (GLP-1) Receptor Agonists, Pioglitazone and Vitamin E for Liver Histology among Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Pilot Network Meta-Analysis of Randomized Controlled Trials","volume":"17","author":"Gu","year":"2023","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus Placebo in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pooled Analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Randomised Trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of Semaglutide on Cardiac Structure and Function in Patients with Obesity-Related Heart Failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus Placebo in People with Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF DM Randomised Trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure: A Prespecified Analysis of the SELECT Trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.jacc.2024.08.023","article-title":"Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure with Preserved Ejection Fraction","volume":"84","author":"Verma","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM Trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"177953","DOI":"10.1016\/j.ejphar.2025.177953","article-title":"Impact of Semaglutide on Lipid Profiles in Overweight and Obese Non-Diabetic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"1003","author":"Miranda","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kennedy, C., Hayes, P., Salama, S., Hennessy, M., and Fogacci, F. (2023). The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030772"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41366-024-01646-9","article-title":"Semaglutide Effects on Safety and Cardiovascular Outcomes in Patients with Overweight or Obesity: A Systematic Review and Meta-Analysis","volume":"49","author":"Cleto","year":"2025","journal-title":"Int. J. Obes."},{"key":"ref_48","first-page":"A4145254","article-title":"Abstract 4145254: Effects of Semaglutide on Safety Outcomes in Patients with Type 2 Diabetes Mellitus And High Cardiovascular Risk: A Meta-Analysis Of Randomized Controlled Trials And Systematic Review","volume":"150","author":"Mazetto","year":"2024","journal-title":"Circulation"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide Safety and Efficacy in Patients with Non-Alcoholic Steatohepatitis (LEAN): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination Therapy for Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1038\/s41467-025-62891-8","article-title":"A Retrospective Analysis of Combination Therapy with GLP-1 Receptor Agonists and SGLT2 Inhibitors versus SGLT2 Inhibitor Monotherapy in Patients with MASLD","volume":"16","author":"Wu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction\u2013Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2147\/DMSO.S443396","article-title":"The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight\/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","volume":"17","author":"Lv","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e240259","DOI":"10.1530\/JOE-24-0259","article-title":"Cardiovascular Effects of Tirzepatide","volume":"264","author":"Sumithran","year":"2025","journal-title":"J. Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A Phase IIa Active-Comparator-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide in Patients with Non-Alcoholic Fatty Liver Disease","volume":"79","author":"Lawitz","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1111\/dom.15693","article-title":"Glucagon Agonism in the Treatment of Metabolic Diseases Including Type 2 Diabetes Mellitus and Obesity","volume":"26","author":"Winther","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101483","DOI":"10.1016\/j.jhepr.2025.101483","article-title":"Safety and Efficacy of 24 Weeks of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Controlled Clinical Trial","volume":"7","author":"Browne","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","article-title":"Safety and Efficacy of Weekly Pemvidutide versus Placebo for Metabolic Dysfunction-Associated Steatohepatitis (IMPACT): 24-Week Results from a Multicentre, Randomised, Double-Blind, Phase 2b Study","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"A13440","DOI":"10.1161\/circ.146.suppl_1.13440","article-title":"Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1\/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators","volume":"146","author":"Plutzky","year":"2022","journal-title":"Circulation"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 Receptor Dual Agonist Survodutide for Obesity: A Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Trial","volume":"12","author":"Steen","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/S0168-8278(20)30765-0","article-title":"HM15211, a Novel GLP-1\/GIP\/Glucagon Triple-Receptor Co-Agonist Significantly Reduces Liver Fat and Body Weight in Obese Subjects with Non-Alcoholic Fatty Liver Disease: A Phase 1b\/2a, Multi-Center, Randomized, Placebo-Controlled Trial","volume":"73","author":"Abdelmalek","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1096\/fj.15-273771","article-title":"GPR119: A Promising Target for Nonalcoholic Fatty Liver Disease","volume":"30","author":"Yang","year":"2016","journal-title":"FASEB J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S0168-8278(25)00424-6","article-title":"LBP-005 DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-Week Randomized Placebocontrolled Trial in Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients","volume":"82","author":"Kim","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S576","DOI":"10.1016\/S0168-8278(24)01698-2","article-title":"THU-232 Additive Hepatoprotective Effects of DA-1241, a Novel GPR119 Agonist, in Combination with Semaglutide in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH","volume":"80","author":"Lewinska","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2158-LB","DOI":"10.2337\/db25-2158-LB","article-title":"2158-LB: Additive Hepatoprotective Effects of DA-1241, a GPR119 Agonist, in Combination with Efruxifermin in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH","volume":"74","author":"Chae","year":"2025","journal-title":"Diabetes"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X Receptor: A Master Regulator of Hepatic Triglyceride and Glucose Homeostasis","volume":"36","author":"Jiao","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.gastha.2023.09.013","article-title":"Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases","volume":"3","author":"Almeqdadi","year":"2024","journal-title":"Gastro Hep Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and Renal Improvements with FXR Agonist Vonafexor in Individuals with Suspected Fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S812","DOI":"10.1016\/S0168-8278(23)02270-5","article-title":"HPG1860 in Patients with NASH: A Phase II Double-Blind, Placebo-Controlled, Dose-Ranging Study","volume":"78","author":"Alkhouri","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.clinre.2025.102530","article-title":"Assessing the Efficacy of Farnesoid X Receptor Agonists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis","volume":"49","author":"Kumar","year":"2025","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/cvr\/cvy093","article-title":"Adiponectin Determines Farnesoid X Receptor Agonism-Mediated Cardioprotection against Post-Infarction Remodelling and Dysfunction","volume":"114","author":"Xia","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00592-020-01652-z","article-title":"Farnesoid X Receptor (FXR) Agonist Ameliorates Systemic Insulin Resistance, Dysregulation of Lipid Metabolism, and Alterations of Various Organs in a Type 2 Diabetic Kidney Animal Model","volume":"58","author":"Han","year":"2021","journal-title":"Acta Diabetol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"114089","DOI":"10.1016\/j.ejmech.2021.114089","article-title":"Discovery of a Tricyclic Farnesoid X Receptor Agonist HEC96719, a Clinical Candidate for Treatment of Non-Alcoholic Steatohepatitis","volume":"230","author":"Cao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsbmb.2016.07.004","article-title":"Cardiopulmonary Protective Effects of the Selective FXR Agonist Obeticholic Acid in the Rat Model of Monocrotaline-Induced Pulmonary Hypertension","volume":"165","author":"Vignozzi","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.112.196519","article-title":"Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (\u2212\/\u2212) Mice","volume":"343","author":"Hambruch","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.scib.2021.03.019","article-title":"Efficacy and Safety of Chiglitazar, a Novel Peroxisome Proliferator-Activated Receptor Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial (CMAP)","volume":"66","author":"Ji","year":"2021","journal-title":"Sci. Bull."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12933-019-0864-7","article-title":"The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARM\u03b1) Paradigm: Conceptual Framework and Therapeutic Potential: A Consensus Statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation","volume":"18","author":"Fruchart","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e13057","DOI":"10.1002\/jgh3.13057","article-title":"Impact of Pemafibrate in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated by Dyslipidemia: A Single-arm Prospective Study","volume":"8","author":"Ono","year":"2024","journal-title":"JGH Open"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"Glynn","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_85","first-page":"42","article-title":"Pemafibrate and Cardiac Reverse Remodeling in Patients with Systolic Heart Failure Receiving Guideline-Directed Medical Therapy","volume":"31","author":"Hida","year":"2025","journal-title":"J. Cardiol. Cases"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s13340-023-00645-x","article-title":"Effects of Pemafibrate on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes Mellitus: A Pilot Study","volume":"14","author":"Yamamoto","year":"2023","journal-title":"Diabetol. Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s13340-025-00845-7","article-title":"Effect of Tofogliflozin on Obesity-Related Health Problems in Patients with Type 2 Diabetes and Overweight or Obesity\u2014A Post-Hoc Sub-Analysis of the UTOPIA Study","volume":"16","author":"Katakami","year":"2025","journal-title":"Diabetol. Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/jdi.14402","article-title":"Post-hoc Analysis of the Tofogliflozin Post-marketing Surveillance Study (J- STEP\/LT): Tofogliflozin Improves Liver Function in Type 2 Diabetes Patients Regardless of BMI","volume":"16","author":"Uchinuma","year":"2025","journal-title":"J. Diabetes Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13578-024-01267-9","article-title":"New Advances in Drug Development for Metabolic Dysfunction-Associated Diseases and Alcohol-Associated Liver Disease","volume":"14","author":"Zhang","year":"2024","journal-title":"Cell Biosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Menezes Junior, A.D.S., Oliveira, V.M.R., Oliveira, I.C., De Sousa, A.M., Santana, A.J.P., Carvalho, D.P.C., Paro Piai, R.F., Matos, F.H., De Paiva, A.M., and Reis, G.B.B. (2023). Dual PPR\u03b1\u03d2 Agonists for the Management of Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J. Clin. Med., 12.","DOI":"10.3390\/jcm12175674"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2014.3321","article-title":"Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients with Type 2 Diabetes Mellitus: The AleCardio Randomized Clinical Trial","volume":"311","author":"Lincoff","year":"2014","journal-title":"JAMA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MPG.0000000000003796","article-title":"An Open Label, Randomized, Multicenter Study of Elafibranor in Children with Nonalcoholic Steatohepatitis","volume":"77","author":"Goyal","year":"2023","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/MS9.0000000000002868","article-title":"Latest FDA Approved Drug Elafibranor (Iqirvo): A Novel Prospect for Treatment of Primary Biliary Cholangitis","volume":"87","author":"Hasibuzzaman","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"154707","DOI":"10.1016\/j.metabol.2021.154707","article-title":"Elafibranor Improves Diet-Induced Nonalcoholic Steatohepatitis Associated with Heart Failure with Preserved Ejection Fraction in Golden Syrian Hamsters","volume":"117","author":"Briand","year":"2021","journal-title":"Metabolism"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1038\/s41598-021-83974-8","article-title":"Beneficial Effects of Elafibranor on NASH in E3L.CETP Mice and Differences between Mice and Men","volume":"11","author":"Verschuren","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The Pan-PPAR Agonist Lanifibranor Improves Cardiometabolic Health in Patients with Metabolic Dysfunction-Associated Steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"177945","DOI":"10.1016\/j.ejphar.2025.177945","article-title":"Lanifibranor and Semaglutide Demonstrate Multiple Metabolic Benefits in Free-Choice Diet Induced Obese Hamster Models of MASH and MetALD","volume":"1003","author":"Briand","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13075-021-02592-x","article-title":"The Pan-PPAR Agonist Lanifibranor Reduces Development of Lung Fibrosis and Attenuates Cardiorespiratory Manifestations in a Transgenic Mouse Model of Systemic Sclerosis","volume":"23","author":"Clark","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"117826","DOI":"10.1016\/j.biopha.2025.117826","article-title":"The Pan-PPAR Agonist Lanifibranor Reduces Portal Pressure Independent of Fibrosis Reduction through the Splanchnic Vasculature","volume":"183","author":"Heldens","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_102","first-page":"334","article-title":"Efficacy and safety of chiglitazar in type 2 diabetes: A multi-center, randomized, double-blind, and parallel group clinical trial","volume":"11","author":"Lyu","year":"2019","journal-title":"Chin. J. Diabetes Mellit."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1111\/dom.70009","article-title":"Efficacy and Safety of Chiglitazar Add-on to Metformin in Type 2 Diabetes Mellitus (RECAM Study)","volume":"27","author":"Gao","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1124\/jpet.118.255216","article-title":"RLA8\u2014A New and Highly Effective Quadruple PPAR-\u03b1\/\u03b3\/\u03b4 and GPR40 Agonist to Reverse Nonalcoholic Steatohepatitis and Fibrosis","volume":"369","author":"Li","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"114061","DOI":"10.1016\/j.ejmech.2021.114061","article-title":"Discovery of New and Highly Effective Quadruple FFA1 and PPAR\u03b1\/\u03b3\/\u03b4 Agonists as Potential Anti-Fatty Liver Agents","volume":"229","author":"Zhou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_106","first-page":"S1","article-title":"An unimolecular GLP-1R\/GIPR\/Pan-PPAR quintuple agonist eliminates obesity and insulin resistance in mice","volume":"68","author":"Liskiewicz","year":"2025","journal-title":"Diabetologia"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Longo, M., Paolini, E., Di Benedetto, P., Tomassini, E., Meroni, M., and Dongiovanni, P. (2024). DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25169074"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"100676","DOI":"10.1016\/j.jlr.2024.100676","article-title":"Targeting acetyl-CoA carboxylases for the treatment of MASLD","volume":"65","year":"2024","journal-title":"J Lipid Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cmet.2024.10.013","article-title":"A Hierarchical Hepatic de Novo Lipogenesis Substrate Supply Network Utilizing Pyruvate, Acetate, and Ketones","volume":"37","author":"Rauckhorst","year":"2025","journal-title":"Cell Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 2b Trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2468-1253(25)00128-1","article-title":"Efficacy and Safety of Ervogastat Alone and in Combination with Clesacostat in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis and F2\u2013F3 Fibrosis (MIRNA): Results from a Phase 2, Randomised, Double-Blind, Double-Dummy Study","volume":"10","author":"Wong","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_112","unstructured":"Madrigal Pharmaceuticals Inc. (2026, February 27). Madrigal Expands Its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor. Available online: https:\/\/www.globenewswire.com\/news-release\/2026\/01\/09\/3216039\/0\/en\/Madrigal-Expands-its-MASH-Pipeline-with-Exclusive-Global-License-Agreement-for-Ervogastat-a-Phase-2-Oral-DGAT-2-Inhibitor.html."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and Efficacy of Combination Therapy with Semaglutide, Cilofexor and Firsocostat in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Open-Label Phase II Trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense Oligonucleotide DGAT-2 Inhibitor, ION224, for Metabolic Dysfunction-Associated Steatohepatitis (ION224-CS2): Results of a 51-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"406","author":"Loomba","year":"2025","journal-title":"Lancet"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/HEP.0000000000000980","article-title":"Aramchol Improves Hepatic Fibrosis in Metabolic Dysfunction\u2013Associated Steatohepatitis: Results of Multimodality Assessment Using Both Conventional and Digital Pathology","volume":"81","author":"Ratziu","year":"2025","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1982-LB","DOI":"10.2337\/db25-1982-LB","article-title":"1982-LB: MPC-Directed Insulin Sensitizer MSDC-0602K Combines with Tirzepatide to Maintain Muscle Mass\/Function and Restructure Adipose Tissue","volume":"74","author":"Abubaker","year":"2025","journal-title":"Diabetes"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin Sensitizer MSDC-0602K in Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S0168-8278(24)00577-4","article-title":"LBP-010 Azemiglitazone in combination with GLP1 agonists increases benefit and could preserve lean body mass","volume":"80","author":"Colca","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jhep.2024.06.034","article-title":"Should the New EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on MASLD Recommend Pioglitazone as a MASH-Targeted Pharmacotherapy?","volume":"82","author":"Sposito","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065\u2014Deuterium-Stabilized (R)-Pioglitazone in Patients with NASH: A Phase II Randomized Placebo-Controlled Trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"ehaf784.4780","DOI":"10.1093\/eurheartj\/ehaf784.4780","article-title":"Therapeutic Potential of Pxl065 (Deuterium-Stabilized r-Enantiomer of Pioglitazone) in Hypertrophic Cardiomyopathy","volume":"46","author":"Pfaller","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Falamarzi, K., Malekpour, M., Tafti, M.F., Azarpira, N., Behboodi, M., and Zarei, M. (2022). The Role of FGF21 and Its Analogs on Liver Associated Diseases. Front. Med., 9.","DOI":"10.3389\/fmed.2022.967375"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/CRD.0000000000000625","article-title":"Pegozafermin Is a Potential Master Therapeutic Regulator in Metabolic Disorders: A Review","volume":"33","author":"Bailey","year":"2025","journal-title":"Cardiol. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.metabol.2018.11.006","article-title":"High Plasma FGF21 Levels Predicts Major Cardiovascular Events in Patients Treated with Atorvastatin (from the Treating to New Targets [TNT] Study)","volume":"93","author":"Ong","year":"2019","journal-title":"Metabolism"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/ATVBAHA.113.301599","article-title":"Serum Fibroblast Growth Factor-21 Levels Are Associated with Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors","volume":"33","author":"Chow","year":"2013","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbrc.2015.02.081","article-title":"FGF21 Attenuates Pathological Myocardial Remodeling Following Myocardial Infarction through the Adiponectin-Dependent Mechanism","volume":"459","author":"Joki","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/cvr\/cvab076","article-title":"Pharmacological Treatment with FGF21 Strongly Improves Plasma Cholesterol Metabolism to Reduce Atherosclerosis","volume":"118","author":"Liu","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Peng, Z., Gao, L., Zhang, L., Yao, R., Li, X., Deng, L., Fan, J., Ying, L., and Wang, Y. (2025). Development of FGF21 Mutant with Potent Cardioprotective Effects in T2D Mice via FGFR1\u2013AMPK-Mediated Inhibition of Oxidative Stress. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146577"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1097\/CM9.0000000000001890","article-title":"The Role of FGF21 in the Pathogenesis of Cardiovascular Disease","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin. Med. J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in Patients with Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in Patients with Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/psp4.13111","article-title":"Simulation-based Evaluation of Personalized Dosing Approaches for anti-FGFR\/KLB Bispecific Antibody Fazpilodemab","volume":"13","author":"Yoshida","year":"2024","journal-title":"CPT Pharmacom. Syst. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/apt.70038","article-title":"Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-Cirrhotic MASH","volume":"61","author":"Raji","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_135","first-page":"A17","article-title":"P5 Pegozafermin Treatment Demonstrates Long-Term Benefit in Subjects with Metabolic Dysfunction-Associated Steatohepatitis and Fibrosis: Results from the Phase 2b ENLIVEN Clinical Trial","volume":"74","author":"Alazawi","year":"2025","journal-title":"Gut"},{"key":"ref_136","first-page":"110709","article-title":"Safety and Efficacy of Efruxifermin in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review","volume":"16","author":"Borozan","year":"2025","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin Alfa (BOS-580), a Long-Acting FGF21 Analogue, in Participants with Phenotypic Metabolic Dysfunction-Associated Steatohepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial","volume":"10","author":"Loomba","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_138","first-page":"7","article-title":"Once-Monthly Efimosfermin Alfa for Up to 48 Weeks in MASH with F2\/F3 Fibrosis: Results from a Phase 2, Open-Label Extension Study","volume":"21","author":"Noureddin","year":"2025","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"103786","DOI":"10.1016\/j.jpet.2025.103786","article-title":"Efficacy and Safety of Fibroblast Growth Factor 21 Analogs in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease and Metabolic Dysfunction\u2013Associated Steatohepatitis: A Systematic Review and Network Meta-Analysis","volume":"393","author":"Abdeljawad","year":"2026","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2024.10.048","article-title":"PNPLA3(148M) Is a Gain-of-Function Mutation That Promotes Hepatic Steatosis by Inhibiting ATGL-Mediated Triglyceride Hydrolysis","volume":"82","author":"Wang","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e16186","DOI":"10.1111\/liv.16186","article-title":"Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis","volume":"45","author":"Tesz","year":"2025","journal-title":"Liver Int."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1210\/clinem\/dgae264","article-title":"LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases","volume":"110","author":"Zhang","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 Antisense Oligonucleotide, for the Treatment of MASH in 148M Homozygous Participants: Two Randomized Phase I Trials","volume":"83","author":"Armisen","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_144","unstructured":"(2026, February 27). Clinical Trials Appendix: 3Q 2025 Results Update. Available online: https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2025\/9m-q3\/9M-and-Q3-2025-results-clinical-trials-appendix.pdf."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4254\/wjh.v15.i2.201","article-title":"Galectin-3 Inhibition as a Potential Therapeutic Target in Non-Alcoholic Steatohepatitis Liver Fibrosis","volume":"15","author":"Kram","year":"2023","journal-title":"World J. Hepatol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Liu, H., Hwang, S.-Y., and Lee, S.S. (2023). Role of Galectin in Cardiovascular Conditions Including Cirrhotic Cardiomyopathy. Pharmaceuticals, 16.","DOI":"10.3390\/ph16070978"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2015.05.040","article-title":"Predictive Value of Galectin-3 for Incident Cardiovascular Disease and Heart Failure in the Population-Based FINRISK 1997 Cohort","volume":"192","author":"Jagodzinski","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e015405","DOI":"10.1161\/JAHA.119.015405","article-title":"Levels and Change in Galectin-3 and Association with Cardiovascular Events: The ARIC Study","volume":"9","author":"Aguilar","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis with Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Comeglio, P., Guarnieri, G., Filippi, S., Cellai, I., Acciai, G., Holyer, I., Zetterberg, F., Leffler, H., Kahl-Knutson, B., and Sarchielli, E. (2024). The Galectin-3 Inhibitor Selvigaltin Reduces Liver Inflammation and Fibrosis in a High Fat Diet Rabbit Model of Metabolic-Associated Steatohepatitis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1430109"},{"key":"ref_153","first-page":"S127","article-title":"Belapectin reduces liver stiffness progression and prevents varices at 18 months in MASH cirrhosis: Results: From the NAVIGATE trial","volume":"82","author":"Vuppalanchi","year":"2025","journal-title":"Hepatology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40261-024-01395-7","article-title":"Single-Dose Pharmacokinetics and Safety of the Oral Galectin-3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment","volume":"44","author":"Aslanis","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"172701","DOI":"10.1016\/j.ejphar.2019.172701","article-title":"Cardioprotective Effects of Galectin-3 Inhibition against Ischemia\/Reperfusion Injury","volume":"863","author":"Mo","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1093\/cvr\/cvad116","article-title":"Inhibition of Galectin-3 Post-Infarction Impedes Progressive Fibrosis by Regulating Inflammatory Profibrotic Cascades","volume":"119","author":"Wang","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/glycob\/cwt006","article-title":"Inhibition of Galectin-3 Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice","volume":"23","author":"MacKinnon","year":"2013","journal-title":"Glycobiology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1872-034X.2007.00297.x","article-title":"Ursodeoxycholic Acid: Mechanism of Action and Novel Clinical Applications","volume":"38","author":"Ikegami","year":"2008","journal-title":"Hepatol. Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e2462185","DOI":"10.1001\/jamanetworkopen.2024.62185","article-title":"Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial","volume":"8","author":"Ji","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/FJC.0000000000001308","article-title":"Efficacy and Underlying Mechanism of Berberine Against Atherosclerosis: A Meta-Analysis in Preclinical Animal Studies","volume":"80","author":"Jia","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"851","DOI":"10.14348\/molcells.2015.0094","article-title":"Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting Endoplasmic Reticulum (ER) Stress Induced by Disturbed Flow","volume":"38","author":"Chung","year":"2015","journal-title":"Mol. Cells"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Chung, J., An, S.H., Kang, S.W., and Kwon, K. (2016). Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147839"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A Phase 2, Proof of Concept, Randomised Controlled Trial of Berberine Ursodeoxycholate in Patients with Presumed Non-Alcoholic Steatohepatitis and Type 2 Diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12944-020-01406-4","article-title":"Pharmacokinetics and Pharmacodynamics of HTD1801 (Berberine Ursodeoxycholate, BUDCA) in Patients with Hyperlipidemia","volume":"19","author":"Watts","year":"2020","journal-title":"Lipids Health Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.17116\/terarkh2014861248-52","article-title":"Ursodeoxycholic Acid-Enhanced Efficiency and Safety of Statin Therapy in Patients with Liver, Gallbladder, and\/or Biliary Tract Diseases: The RACURS Study","volume":"86","author":"Martsevich","year":"2014","journal-title":"Ter. Arkhiv"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Etzion, O., Bareket-Samish, A., Yardeni, D., and Fishman, P. (2024). Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma. Biomedicines, 12.","DOI":"10.3390\/biomedicines12040848"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.16664","article-title":"Randomised Clinical Trial: A Phase 2 Double-blind Study of Namodenoson in Non-alcoholic Fatty Liver Disease and Steatohepatitis","volume":"54","author":"Safadi","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18103\/mra.v13i2.6343","article-title":"The Neuro- Cardio- and Hepato- Protective Effects of Namodenoson Are Mediated by Adiponectin","volume":"13","author":"Etzion","year":"2025","journal-title":"Med Res. Arch."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2025.01.032","article-title":"A Phase IIb Randomised-Controlled Trial of the FFAR1\/FFAR4 Agonist Icosabutate in MASH","volume":"83","author":"Harrison","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"100997","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of Omega-3 Fatty Acids on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis","volume":"38","author":"Khan","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/2012.jama.11374","article-title":"Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Meta-Analysis","volume":"308","author":"Rizos","year":"2012","journal-title":"JAMA"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"24","DOI":"10.31083\/j.rcm2401024","article-title":"Omega-3 Polyunsaturated Fatty Acids Supplements and Cardiovascular Disease Outcome: A Systematic Review and Meta-Analysis on Randomized Controlled Trials","volume":"24","author":"Qi","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000445047","article-title":"Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia","volume":"135","author":"Kastelein","year":"2016","journal-title":"Cardiology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacl.2015.10.012","article-title":"Icosabutate for the Treatment of Very High Triglycerides: A Placebo-Controlled, Randomized, Double-Blind, 12-Week Clinical Trial","volume":"10","author":"Bays","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"ref_175","unstructured":"Harrison, S., Montilla, A., Alonso, C., Jeannin, S., Steineger, H., Skj\u00e6ret, T., and Fraser, D. (2025, January 7\u201311). ICONA Study Investigators. Decreased serum concentrations of pro-inflammatory oxylipins in MASH patients treated with icosabutate (ICONA study). Proceedings of the AASLD The Liver Meeting, Washington, DC, USA."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/oby.23282","article-title":"Omega-6 and Omega-3 Oxylipins as Potential Markers of Cardiometabolic Risk in Young Adults","volume":"30","author":"Di","year":"2022","journal-title":"Obesity"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.archger.2015.04.007","article-title":"Plasma Soluble Vascular Adhesion Protein-1 Concentration Correlates with Arterial Stiffness: A Cross-Sectional Study","volume":"61","author":"Chen","year":"2015","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Li, H., Du, S., Niu, P., Gu, X., Wang, J., and Zhao, Y. (2021). Vascular Adhesion Protein-1 (VAP-1)\/Semicarbazide-Sensitive Amine Oxidase (SSAO): A Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseases. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.679707"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"9249","DOI":"10.1038\/s41598-018-27551-6","article-title":"Inhibition of Semicarbazide-Sensitive Amine Oxidase Reduces Atherosclerosis in Cholesterol-Fed New Zealand White Rabbits","volume":"8","author":"Wang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.trsl.2018.03.001","article-title":"Inhibition of Semicarbazide-Sensitive Amine Oxidase Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice","volume":"197","author":"Wang","year":"2018","journal-title":"Transl. Res."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Vakal, S., Jalkanen, S., Dahlstr\u00f6m, K.M., and Salminen, T.A. (2020). Human Copper-Containing Amine Oxidases in Drug Design and Development. Molecules, 25.","DOI":"10.3390\/molecules25061293"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Zhang, J., Xue, C., Zhu, T., Vivekanandan, A., Pennathur, S., Ma, Z.A., and Chen, Y.E. (2013). A Tripeptide Diapin Effectively Lowers Blood Glucose Levels in Male Type 2 Diabetes Mice by Increasing Blood Levels of Insulin and GLP-1. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083509"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"eaaz2841","DOI":"10.1126\/scitranslmed.aaz2841","article-title":"Glycine-Based Treatment Ameliorates NAFLD by Modulating Fatty Acid Oxidation, Glutathione Synthesis, and the Gut Microbiome","volume":"12","author":"Rom","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"102313","DOI":"10.1016\/j.redox.2022.102313","article-title":"Induction of Glutathione Biosynthesis by Glycine-Based Treatment Mitigates Atherosclerosis","volume":"52","author":"Rom","year":"2022","journal-title":"Redox Biol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"ofz112","DOI":"10.1093\/ofid\/ofz112","article-title":"Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study","volume":"6","author":"Francisci","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Hwang, I., Lee, S.-R., Kim, H.J., Kim, Y., and Lee, S.W. (2025). Safety, Pharmacokinetics, and Food Effect of the ROR\u03b1 Agonist TB-840, a Novel Candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Randomized First-in-Human Study in Healthy Volunteers. Life, 15.","DOI":"10.3390\/life15091410"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Chen, Y., Zhang, S.-P., Gong, W.-W., Zheng, Y.-Y., Shen, J.-R., Liu, X., Gu, Y.-H., Shi, J.-H., and Meng, G.-L. (2023). Novel Therapeutic Potential of Retinoid-Related Orphan Receptor \u03b1 in Cardiovascular Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043462"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the Treatment of Non-Alcoholic Steatohepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12020-023-03636-9","article-title":"The Effect of Semaglutide on Blood Pressure in Patients with Type-2 Diabetes: A Systematic Review and Meta-Analysis","volume":"83","author":"Wu","year":"2024","journal-title":"Endocrine"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and Efficacy of Once-Weekly Efruxifermin versus Placebo in Non-Alcoholic Steatohepatitis (HARMONY): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and Efficacy of Efruxifermin in Combination with a GLP-1 Receptor Agonist in Patients with NASH\/MASH and Type 2 Diabetes in a Randomized Phase 2 Study","volume":"23","author":"Harrison","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in Compensated Liver Cirrhosis Caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/FJC.0000000000000891","article-title":"The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPAR\u03b1 and PPAR\u03b3 Activation","volume":"76","author":"Kalliora","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Xi, Y., Zhang, Y., Zhu, S., Luo, Y., Xu, P., and Huang, Z. (2020). PPAR-Mediated Toxicology and Applied Pharmacology. Cells, 9.","DOI":"10.3390\/cells9020352"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Mer\u0107ep, I., Vujevi\u0107, A., Striki\u0107, D., Radman, I., Pe\u0107in, I., and Reiner, \u017d (2023). Present and Future of Dyslipidaemia Treatment-A Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185839"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Vatri, M., Faggiano, A., Angelino, E., Ambrosetti, M., Faggiano, P.M., and Fattirolli, F. (2026). Therapeutic Inertia in Lipid-Lowering Treatment: A Narrative Review. J. Clin. Med., 15.","DOI":"10.3390\/jcm15031075"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and Opportunities in NASH Drug Development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Rinella, M.E., and Sookoian, S. (Nat. Rev. Gastroenterol. Hepatol., 2026). Therapeutic Targets for Metabolic Dysfunction-Associated Steatohepatitis: A Personalized Approach to Disease Management, Nat. Rev. Gastroenterol. Hepatol., Online ahead of print.","DOI":"10.1038\/s41575-026-01187-8"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.3350\/cmh.2024.0438","article-title":"Precision Medicine and Nucleotide-Based Therapeutics to Treat Steatotic Liver Disease","volume":"31","author":"Caddeo","year":"2025","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/4\/909\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T12:04:10Z","timestamp":1776341050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/4\/909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":204,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["biomedicines14040909"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines14040909","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}